Ovid Therapeutics Inc. is a biopharmaceutical company focused on improving the lives of people with epilepsies and brain conditions with seizure symptoms. It advances a pipeline of novel, targeted small molecule candidates that modulate factors involved in neuronal hyperexcitability. Key developments include OV888 (GV101), a ROCK2 inhibitor for cerebral cavernous malformations; OV329, a GABA-aminotransferase inhibitor for treatment-resistant seizures; and OV350, a KCC2 transporter activator for epilepsies and psychiatric conditions. It also develops soticlestat, a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes. The OVID stock yearly return is shown above.
The yearly return on the OVID stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2024 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OVID annual return calculation with any dividends reinvested as applicable (on ex-dates).
|